Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to <17 years.

Phase 4

Baudax Bio

Meloxicam